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Abstract
Introduction: Metoprolol is a widely used beta-adrenergic blocker that is commonly prescribed for a variety of
cardiovascular syndromes and conditions. While central nervous system adverse effects have been well-described
with most beta-blockers (especially lipophilic agents such as propranolol), visual hallucinations have been only
rarely described with metoprolol.
Case presentations: Case 1 was an 84-year-old Caucasian woman with a history of hypertension and
osteoarthritis, who suffered from visual hallucinations which she described as people in her bedroom at night.
They would be standing in front of the bed or sitting on chairs watching her when she slept. Numerous
medications were stopped before her physician realized the metoprolol was the causative agent. The hallucinations
resolved only after discontinuation of this medication.
Case 2 was a 62-year-old Caucasian man with an inferior wall myocardial infarction complicated by cardiac arrest,
who was successfully resuscitated and discharged from the hospital on metoprolol. About 18 months after
discharge, he related to his physician that he had been seeing dead people at night. He related his belief that
since he ‘had died and was brought back to life’, he was now seeing people from the after-life. Upon
discontinuation of the metoprolol the visual disturbances resolved within several days.
Case 3 was a 68 year-old Caucasian woman with a history of severe hypertension and depression, who reported
visual hallucinations at night for years while taking metoprolol. These included awakening during the night with
people in her bedroom and seeing objects in her room turn into animals. After a new physician switched her from
metoprolol to atenolol, the visual hallucinations ceased within four days.
Conclusion: We suspect that metoprolol-induced visual hallucinations may be under-recognized and under-
reported. Patients may frequently fail to acknowledge this adverse effect believing that they are just dreaming, or
may be embarrassed to report visions that they feel will not be perceived by others to be real. Similarly, healthcare
providers can also fail to recognize this visual toxicity or attribute visual hallucinations to concurrent illness or other
medications. Clinicians must maintain diligent surveillance when managing patients receiving this drug.
Introduction
The central nervous system (CNS) adverse effects of
beta-adrenergic blockers, including visual hallucinations,
have been largely associated with highly lipophilic agents
such as propranolol, timolol and pindolol [1,2]. Meto-
prolol is one of the most commonly prescribed beta-
adrenergic blocking agents but visual hallucinations
associated with its use have been reported only rarely
[3-5]. Here, the cases of three patients with visual hallu-
cinations induced by metoprolol are reported; we review
the literature on this topic and hypothesize why this
neurologic toxicity may be under-recognized and under-
reported.
Case presentations
Case 1
An 84-year-old Caucasian woman with a history of
hypertension and osteoarthritis suffered from visual hal-
lucinations for several years. She would awake at night
to see people standing at the foot of her bed or sitting
on a chair in her room watching her sleep. These people
would not converse with her but were frightening. She
had no history of neurological or psychiatric illness nor
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physical examination. Her medications consisted of
aspirin, a calcium channel blocker, an angiotensin con-
verting enzyme inhibitor and metoprolol tartrate 50 mg
orally twice a day for blood pressure control. She used
acetaminophen for control of her arthritis symptoms.
She did not have any hallucinations any other time of
day or night. A neurological work up included a mag-
netic resonance imaging of her brain, an electroencepha-
lography and neurocognitive testing, which was
unrevealing. A full complement of laboratory tests
showed normal thyroid functions, vitamin B12 and
folate levels. She had no history of alcohol or drug use.
She was unsure how long she had been on all of her
medications but knew that she had been taking meto-
prolol for at least two years. All of her antihypertensive
medications were discontinued besides the beta adrener-
gic blocker before her physician realized the causative
agent was metoprolol. Her visual hallucinations stopped
completely within several days of ceasing this
medication.
Case 2
A 62-year-old Caucasian man had an inferior wall myo-
cardial infarction that was complicated by cardiac arrest
shortly after arrival to the emergency department. He
was successfully resuscitated after approximately one to
two minutes of ventricular fibrillation with electrical
defibrillation. He otherwise had an uneventful recovery
and was discharged from the hospital on aspirin, isosor-
bide, lisinopril and metoprolol tartrate 100 mg orally
twice a day. He had no history of neurologic or psychia-
tric abnormalities or significant findings in this regard
on physical examination. He used alcohol rarely but
there was no illicit drug use.
About 18 months after discharge, our patient asked to
speak to his physician in a confidential manner. He asked
that his wife not be told, and subsequently related that he
had been seeing dead people at night. He would awake
and see faceless figures sitting at the side of his bed; the
figures would vanish as he became totally awake. He
believed that since he ‘h a dd i e da n dw a sb r o u g h tb a c kt o
life’ during the acute phase of his myocardial infarction,
he was now seeing people from the after-life. He would
also see animals at times. The visual hallucinations
started immediately after he was discharged from the
hospital at which time he had been placed on metoprolol.
Upon discontinuation of the metoprolol the visual distur-
bances resolved within several days. Our patient asked to
be restarted on metoprolol after considering the benefi-
cial aspects of the drug on his heart disease. He now
understood that the visual hallucinations were related to
the medication, and they were no longer frightening to
him when they subsequently occurred.
Case 3
A 68-year-old Caucasian woman who suffered from
severe hypertension, hypothyroidism and depression,
reported visual hallucinations at night for two years while
taking metoprolol succinate 100 mg orally once a day.
These included awakening during the night with people
in her bedroom and seeing objects in her room that
turned into animals. Her other medications included
amlodipine, enalapril, escitalopram, levothyroxine and
aspirin. When questioned, she believed the hallucinations
started about the same time that she was placed on meto-
prolol for her hypertension. Her physical examination
and laboratory evaluation were unrevealing. She had no
history of alcohol or illicit drug use. She described the
visual disturbances to her previous family physician, who
felt this was likely related to her medical problems
including her depression. Her neurologic and psychiatric
examinations were otherwise unremarkable except for a
flat affect. She subsequently visited a new physician who
switched her from metoprolol to atenolol, with resolution
of her night-time visual hallucinations within four days.
Discussion
For decades, beta-adrenergic blocking agents have been
known to cause adverse CNS effects including psychiatric
syndromes, bizarre and vivid dreams, sleep disturbances,
delirium, psychosis and visual hallucinations [6,7]. The
medical and pharmacologic literature clearly describe the
highly lipophilic agents, such as propranolol, as most fre-
quently displaying neurologic toxicities [1,8,9]. In 1978,
Fleminger reported an incidence of 14.3% to 17.5% of
visual hallucinations and illusions with propranolol
among patients attending a hypertension clinic [8].
Metoprolol is a popular cardiovascular drug whose
widespread use can be attributed to its generic and
affordable short- and long-acting formulations, and its
established safety and efficacy in treating a variety of
cardiovascular disorders such as hypertension, arrhyth-
mias, angina pectoris, acute coronary syndromes and
congestive heart failure. There is a paucity of data on
the occurrence of CNS side effects with the administra-
tion of metoprolol. Metoprolol, which has an intermedi-
ate degree of lipophilicity (a property known to enhance
CNS drug penetration, as opposed to hydrophilicity,
which limits brain entry), has rarely been reported to
cause visual hallucinations despite its common usage
[3-5]. In light of our experience, we suspect that the
occurrence of visual hallucinations with this drug may
occur more frequently than previously reported.
Under-reporting and under-recognition of hallucinations
caused by metoprolol might be due to several factors.
First, patients may not complain of visual disturbances
because they fail to connect the symptoms with the drug,
as in our second case. Some patients may attribute beta-
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mares [8]. As Fleminger reported with propranolol, all
three of our patients had their visual hallucinations while
awakening from sleep in the hypnopompic state [8].
Furthermore, patients may be too embarrassed to discuss
illusions that they fear may be confused by others as being
a result of mental illness or excessive drug or alcohol use.
Finally, physicians may also fail to recognize this adverse
drug effect and may consider the visual disturbance to be
related to existing medical or psychiatric conditions, as in
our first and third case.
Sirois reported that hallucinations associated with
metoprolol may remain an isolated symptom, or they
may evolve into delirium in older patients with cognitive
deficits [5]. For both of the patients he described, visual
hallucinations began within 24 hours of the initiation of
metoprolol and the side effect was discovered shortly
thereafter during their hospitalization. This is unlike our
patients, who did not recognize the adverse reaction
themselves or have it recognized by their physician for a
long period of time. The delay in diagnosing the cause
of the hallucinations in our patients was either related
to the patient’s reluctance to inform anyone of the visual
disturbances, the patient’s family associating the halluci-
nations with other medical or psychiatric disorders they
thought the patient had or the physician’s inability to
recognize the medication as the etiology for the disor-
der. Our patients had no visual disturbances during
other times nor a psychiatric or medical reason that
would otherwise account for the hallucinations. The hal-
lucinations in the cases described were realistic enough
to cause considerable anxiety and fear for these patients.
Most hallucinations caused by beta-adrenergic agents
typically stop within a few days of drug discontinuation,
as it did in our patients [8,9]. Depending on their diag-
nosis, patients with hallucinations related to metoprolol
may tolerate a switch to a more hydrophilic beta-blocker
such as atenolol or bisoprolol [4].
Interesting, the newer third generation of beta-block-
ers such as nebivolol and carvedilol, which are fre-
quently used to treat those patients with congestive
heart failure and hypertension, thus far have not been
associated with visual hallucinations despite their mod-
erate to high lipophilic nature. Thus it is assumed that
there may be other factors that may influence the degree
of CNS side effects of beta blockers other than lipophili-
city. Other parameters, such as the specific structural
details of the beta-blocker molecules, drug-induced
increases in plasma catecholamine levels and a decrease
in melatonin levels have all been proposed to affect the
beta-blocker penetration of the blood-brain barrier or
the occurrence of CNS side effects [10-12]. These third
generation beta-blockers may be a good alternative to
metoprolol if visual hallucinations occur.
Conclusions
Metoprolol, a widely used beta-blocker, has been asso-
ciated with visual hallucinations and CNS disturbances.
Multiple reasons may lead to under-recognition and
under-reporting of this adverse drug effect, by both
patients and physicians alike. The true incidence of
visual hallucinations related to metoprolol is unknown.
Clinicians are urged to maintain diligent surveillance
when managing patients receiving this drug.
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